viewZelira Therapeutics Ltd.

Zelda Therapeutics teams up with medicinal cannabis clinic network

The agreement supports Zelda’s path to rapid commercialisation through the development of clinically validated cannabis medicines.

collaboration concept
Zelda will pay an initial fee of $40,000 to access existing patient data

Zelda Therapeutics Ltd (ASX:ZLD) has entered into a strategic collaboration agreement with Emerald Clinics to access clinical data from patients treated with medicinal cannabis for pain and insomnia.

Emerald Clinics owns and operates an Australian network of dedicated medicinal cannabis clinics.

Zelda will us this access to real world patient data for its ongoing clinical trial work focused on developing new cannabis-based treatments to reduce opioid usage in patients with chronic pain as well as patients with insomnia and autism.

READ: Zelda Therapeutics responds to ASX query on price and volume increases

Zelda’s managing director Dr Richard Hopkins said: “Australia’s commitment to developing a highly regulated market for prescription cannabis medicines means this country is now a global leader in collection of high-quality longitudinal clinical data relating to patients treated with medicinal cannabis.

“We believe Emerald’s approach to collection and curation of patient data makes this information a very valuable commodity world-wide.”

Option to access future data of patients using Zelda-branded producted

The agreement also includes an option for Zelda to access real-world data collected from patients prescribed Zelda-branded cannabis products, which the company is aiming to bring to market in 2020.

Hopkins added: “Being able to access real-world data, in real-time, from patients treated with regulated cannabis medicines – including, in the near future, our own clinically validated products – will provide Zelda with a significant competitive advantage.

“This information will inform the design of future clinical trials, reduce the risks and costs of development and accelerate the path to market.

“These key value-adding features will further differentiate Zelda from its global peers and enhance the commercialisation opportunities for the company.”

Quick facts: Zelira Therapeutics Ltd.

Price: 0.061 AUD

Market: ASX
Market Cap: $53.22 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Zelira Therapeutics Ltd. named herein, including the promotion by the Company of Zelira Therapeutics Ltd. in any Content on the Site, the...



Full interview: Zelira Therapeutics on recent acquisition with Ilera

Zelira Therapeutics Ltd (ASX:ZLD) founder and chairman Osagie Imasogie and deputy chairman Harry Karelis speaks to Proactive on the recent acquisition of Ilera Therapeutics LLC.  Following overwhelming shareholder support, the merger will create a global medicinal cannabis company called...

on 2/12/19

2 min read